For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD2582La&default-theme=true
RNS Number : 2582L Compre Group Holdings Limited 04 September 2023
Press release
4 September 2023
Compre completes acquisition of Covéa subsidiary
Compre Group Holdings Limited ("Compre"), the Bermuda headquartered
international legacy group, today announces the completion of its acquisition
of the Irish subsidiary of Covéa, Medical Insurance Company DAC (MIC), which
provided insurance policies covering professional medical malpractice risks.
MIC entered into run-off in 2015.
The completion of this complex, cross-border, transaction represents a further
significant step in the build out of Compre's centre of excellence for medical
malpractice in Europe, and follows the approved legal transfer of a portfolio
of French medical malpractice liabilities from another European insurer in
July 2023.
Simon Hawkins, CEO Europe said: "I am delighted to announce the completion of
this transaction following regulatory approval, and I'd like to thank the
Covéa and MIC teams for their ongoing collaboration. This transaction further
demonstrates our client-focused approach to supporting our partners in
achieving their restructuring objectives."
- Ends -
For further information please contact:
Compre
David Haggie / Richard Adams / Olivia Thomson, Haggie
Partners
+44 20 7562 4444
About Compre:
Compre is a leading legacy specialist with over 30 years of experience in the
acquisition and management of discontinued and legacy non-life insurance and
reinsurance business. Compre has experience of acquiring most classes of
direct and reinsurance business, including general liability, marine and motor
liability, workers' compensation and US APH. Compre has operations in Bermuda,
Finland, Germany, Malta, Switzerland, UK, the USA and at Lloyd's.
www.compre-group.com (http://www.compre-group.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END CIRGZGGLNDMGFZG